Patents by Inventor Cuiqin Wang

Cuiqin Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC FUSION POLYPEPTIDE COMPOUND
    Publication number: 20230331779
    Abstract: Provided is a polypeptide compound which is X-ID-Y or Y-ID-X, wherein X is a calcium-sensing receptor agonist; ID is a disulfide bond or linker arm within molecules and links X and Y; and Y is a bone growth peptide receptor agonist or a bone marrow mesenchymal stem cell stimulator. Also provided are a pharmaceutical composition comprising the polypeptide compound and a use of the compound and pharmaceutical composition.
    Type: Application
    Filed: April 20, 2021
    Publication date: October 19, 2023
    Applicant: SHAANXI MICOT TECHNOLOGY CO., LTD.
    Inventor: Cuiqin WANG
  • Compound for treating metabolic diseases and preparation method and use thereof
    Patent number: 11028111
    Abstract: Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound is an activator of FXR and/or a TGR5 receptor, and thus has the activity of activating FXR and/or a TGR5 receptor, and can be used in the preparation of drugs for treating chronic liver diseases, metabolic diseases or portal hypertension.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: June 8, 2021
    Assignee: XI' AN BIOCARE PHARMA LTD.
    Inventors: Guoqin Fu, Wei Ding, Bo Yin, Chao Yang, Cuiqin Wang, Yong Dou, Ruiling Wang
  • COMPOUND FOR TREATING METABOLIC DISEASES AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20200131212
    Abstract: Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The compound is an activator of FXR and/or a TGR5 receptor, and thus has the activity of activating FXR and/or a TGR5 receptor, and can be used in the preparation of drugs for treating chronic liver diseases, metabolic diseases or portal hypertension.
    Type: Application
    Filed: August 15, 2018
    Publication date: April 30, 2020
    Inventors: Guoqin Fu, Wei Ding, Bo Yin, Chao Yang, Cuiqin Wang, Yong Dou, Ruiling Wang